Top 10 Pharma Sales Projections for 2016 – & Beyond

The Top 10 Pharmaceutical Companies

Per the EP Vantage 2016 Preview, the Top 10 pharma companies by expected 2016 sales are:

  1. Pfizer – $48B
  2. Novartis – $44.5B
  3. Roche – $39.8B
  4. Sanofi – $39.7B
  5. Merck – $37.9B
  6. GlaxoSmithKline – $33.5B
  7. Johnson & Johnson – $33.2B
  8. Gilead – $30.1B
  9. AbbVie – $26B
  10. AstraZeneca – $22.7B

 

 

The Top 10 Drugs In 2016

Megablockbuster Humira continues to grab headlines. According to EP Vantage 2016, the top 10 drugs by sales are projected to be:

  1. Humira (adalimumab) – $15.7B
  2. Harvoni (ledipasvir/sofosbuvir) – $11.6B
  3. Rituxan (rituximab) – $7.3B
  4. Avastin (bevacizumab) – $7.0B
  5. Lantus (insulin glargine) – $6.9B
  6. Herceptin (trastuzumab) – $6.8B
  7. Revlimid (lenalidomide) – $6.7B
  8. Prevnar 13 (pneumococcal 13-valent conjugate vaccine) – $6.1B
  9. Remicade (infliximab) – $5.8B
  10. Advair (fluticasone/salmeterol) – $5B
Do you see the pattern? That’s right — biologics. However, several biologics are up for patent loss in the next decade which opens the doors for newly developed and cheaper biosimilars.

__________________________________________________________________________________________

Article Medically reviewed on Aug 22, 2016 by L. Anderson, PharmD for Drugs.com and can be found here.